MedTrace Logo

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

NCT02569242 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 419

Last updated 2022-07-06

Study results available
· View outcomes & findings →

Summary

The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Nivolumab

DRUG

Docetaxel/Paclitaxel

Sponsors & Collaborators

Principal Investigators

  • Ono Pharmaceutical Co., Ltd. Ono Pharmaceutical Co., Ltd. · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-14
Primary Completion
2020-10-23
Completion
2020-10-23

Countries

  • United States
  • Denmark
  • Germany
  • Italy
  • Japan
  • South Korea
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02569242 on ClinicalTrials.gov